Making clinical proteomics 100x more robust and 10x faster
San Diego – ASMS 2018 – (June 4, 2018) – Today, at the 66th Conference on Mass Spectrometry and Allied Topics, Thermo Scientific and Evosep announced a joint effort to develop and promote robust, high-throughput workflows for clinical proteomics.
The collaboration will be centered around work at the Boston-based Thermo Scientific Precision Medicine Science Center where key personnel from all relevant disciplines can be brought to bear on the challenge of truly democratizing proteomics for clinical applications.
“We are using the Evosep One in our new Precision Medicine Science Center in Cambridge, MA, where we have established workflows for the rapid analysis of plasma and FFPE samples” said Ken Miller, VP Omics Marketing at Thermo Fisher Scientific. He continued: “The system works seamlessly with our Q Exactive MS systems and the Evotip technology improves overall system throughput and robustness by reducing column clogging and carryover.”
Nicolai Bache, Head of Applications, Evosep added: “The Evosep One with its novel sample separation solution offers market leading throughput to cope with the significantly larger cohort sizes of typical clinical studies. Researchers are now seeking to include plasma proteomics in an increasing number of clinical studies and therefore it becomes important for the community to have instruments and consumables that are tailored for the task.”
Thermo and Evosep will present data from the joint use of the Evosep One system and Thermo’s QExactive mass spectrometers at ASMS. Several independent academic research groups that have had the instrumentation available since last fall will also present data on posters and in oral presentations.
For more information about the new Evosep One solution, please refer to the recently submitted paper on BioRXiv (1) and visit our booth at ASMS 2018. Alternatively, please call +45 2633 2021, e-mail firstname.lastname@example.org, or visit www.evosep.com.
Evosep aims to improve quality of life and patient care by radically innovating protein-based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than todays’ alternatives. Proteomics is about the study of proteins in a biological mechanism, both their individual function and their combined interactions. For clinical proteomics, the goal is to be able to quickly and efficiently compare a biological sample against a profile panel of selected proteins in order to deliver a diagnose / verdict of healthy or diseased (within given statistical margins). Such a profile is typically called a biomarker and for official approval, it must be demonstrated successfully on a large population. This calls for fast sample processing and because such clinical samples, in the form of blood or biopsies, are much cruder that the relatively clean cell cultures used in basic research, very robust protocols and consumables are also required.
(1) “A novel LC system embeds analytes in pre-formed gradients for rapid, ultra-robust proteomics”, Nicolai Bache, Philipp E. Geyer, Dorte B. Bekker-Jensen, Ole Hoerning, Lasse Falkenby, Peter V. Treit, Sophia Doll, Igor Paron, Florian Meier, Jesper V. Olsen, Ole Vorm, Matthias Mann, bioRxiv 323048; doi: https://doi.org/10.1101/323048